C-NGJ7Itasca Therapeutics
precision oncology, RAS/MAPK pathway
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-NGJ7
C-NGJ7C-NGJ7precision oncology, RAS/MAPK pathway
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Erasca states that its purpose is to erase cancer by tackling oncology’s hardest problems through exceptional science, collaboration, and a modality-agnostic precision oncology approach. The company says it believes the best results for patients will come from keeping an open mind about what is possible, pursuing multiple biological drivers and mechanisms of cancer, and working with world-class collaborators to develop curative therapies.
SourceErasca states that its mission is to erase cancer and that solving oncology’s hardest problems requires staying open to multiple therapeutic approaches rather than being tied to a single drug type or strategy. The company says it believes recent scientific discoveries about biological drivers of cancer, combined with exceptional science, world-class collaborators, partnerships, and agile team-based execution, will produce the greatest results for patients everywhere.
SourceErasca states that its purpose is to erase cancer in patients by developing oncology drugs intended not only to treat but to cure. The company says it believes recent scientific advances make it possible to tackle hard cancer problems, that staying open to multiple drug modalities and treatment approaches will produce the best outcomes for patients, and that artificial intelligence, precision oncology partnerships, and strategies targeting key cancer pathways can accelerate discovery of curative therapies.
SourceNo company beliefs, mission statement, or theory text are visible in the provided Wayback snapshot text; the visible content is only Internet Archive capture metadata and navigation.
Source